Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Micropshere Agent Used with Echocardiography Provides Results Comparable to SPECT

By MedImaging International staff writers
Posted on 25 Feb 2009
A new study concluded that a new microsphere contrast agent used in echocardiography is well tolerated, and that its diagnostic performance in chest pain patients is comparable with single photon emission computed tomography (SPECT) perfusion imaging.

Acusphere, Inc. (Watertown, MA, USA) reported that the study summarized the phase III clinical trial results for Imagify (perflubutane polymer microspheres) for injectable suspension, a cardiovascular drug for the detection of coronary artery disease, the leading cause of death in the United States.

The study was led by Dr. Roxy Senior, consultant cardiologist and director of cardiac research, department of cardiovascular medicine and Institute of Postgraduate Medical Education and Research at Northwick Park Hospital (Harrow, Middlesex, UK), among others. Dr. Senior was the lead clinical investigator for Acusphere's clinical trials for Imagify.

Acusphere is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microsphere technology. The company's lead product candidate, Imagify, is a cardiovascular drug for the detection of coronary artery disease, the leading cause of death in the United States, for which a New Drug Application (NDA) was submitted to the U.S. Food & Drug Administration (FDA) in April 2008 and filed in June 2008. Imagify is designed to enable ultrasound to compete more effectively with nuclear stress testing, the leading procedure for detecting coronary artery disease.

It is estimated that more than 10 million procedures are done each year in the United States to detect coronary artery disease. Imagify and the company's other product candidates were created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microspheres in a versatile manner that allows them to be customized to address the delivery needs of a variety of drugs.

The study was published in the January 2009 issue of the European Journal of Echocardiography.

Related Links:

Acusphere
Northwick Park Hospital


Medical Radiographic X-Ray Machine
TR30N HF
Ultrasonic Pocket Doppler
SD1
X-Ray Illuminator
X-Ray Viewbox Illuminators
New
Mammo DR Retrofit Solution
DR Retrofit Mammography

Channels

Nuclear Medicine

view channel
Image: Perovskite crystal boules are grown in carefully controlled conditions from the melt (Photo courtesy of Mercouri Kanatzidis/Northwestern University)

New Camera Sees Inside Human Body for Enhanced Scanning and Diagnosis

Nuclear medicine scans like single-photon emission computed tomography (SPECT) allow doctors to observe heart function, track blood flow, and detect hidden diseases. However, current detectors are either... Read more

General/Advanced Imaging

view channel
Image: The Angio-CT solution integrates the latest advances in interventional imaging (Photo courtesy of Canon Medical)

Cutting-Edge Angio-CT Solution Offers New Therapeutic Possibilities

Maintaining accuracy and safety in interventional radiology is a constant challenge, especially as complex procedures require both high precision and efficiency. Traditional setups often involve multiple... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.